EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mechanistic insights and in vivo HIV suppression by the BRD4-targeting small molecule ZL0580

Naveen Kumar, Zonghui Ma, Fuquan Long, Srinivasa Reddy Bonam, Hsien-Tsung Lai, Shwu-Yuan Wu, Haiying Chen, Nicholas C Hazell, Jiani Bei, Xuefeng Liu, Yeqing Chen, Zhi Wei und 3 weitere

PLOS Pathogens · 2026

DOI: 10.1371/journal.ppat.1013449 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, 2026. Verfasst von Naveen Kumar und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America. Hauptthemen laut MEDLINE: Transcription Factors, HIV Infections, HIV-1, Nuclear Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NCI NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epigenetic suppression and durable silencing of HIV represent a promising strategy to achieve ART-free remission, consistent with the “block and lock” HIV cure paradigm. BRD4 is a host epigenetic reader and plays a critical role in HIV transcriptional regulation. We previously identified ZL0580, a first-in-class BRD4-selective small molecule distinct from the pan-BET inhibitor JQ1, which induces HIV epigenetic suppression. However, detailed molecular mechanisms, pharmacokinetics (PK), and in vivo HIV-suppressive efficacy of ZL0580 remain undefined. Here, we show that ZL0580 selectively targets BRD4 bromodomain 1 (BD1) through interaction with a key glutamic acid residue (E151), as determined by structural modeling and mutagenesis. Transcriptomic profiling by RNA-seq reveals that ZL0580 and JQ1 induce opposing gene expression programs, consistent with their distinct effects on HIV proviral transcription and latency. In a humanized mouse model of HIV infection, ZL0580 monotherapy, or in combination with ART, potently suppressed active HIV replication, reducing the plasma viremia to nearly undetectable levels, and delayed viral rebound following treatment interruption. Collectively, these findings establish ZL0580 as an epigenetic suppressor of HIV in vivo and provide proof-of-concept for its potential as a “block and lock” HIV cure candidate, warranting further optimization and development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transcription FactorsHIV InfectionsHIV-1Nuclear ProteinsAnti-HIV AgentsAnimalsBromodomain Containing ProteinsHumansCell Cycle ProteinsMiceTriazolesVirus ReplicationAzepines

Substanzen

Bromodomain Containing ProteinsTranscription FactorsCell Cycle ProteinsBRD4 protein, humanNuclear ProteinsTriazoles(+)-JQ1 compoundAnti-HIV AgentsAzepines

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.
  • Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas, United States of America.
  • Department of Sexually Transmitted Disease, Center of Infectious Skin Disease, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.
  • CSIR-Indian Institute of Chemical Technology (IICT), Hyderabad, India.
  • Simmons Comprehensive Cancer Center, Department of Biochemistry, and Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas United States of America.
  • Department of Pathology, The Ohio State University College of Medicine, Columbus, Ohio, United States of America.

ORCID-Profile: Haitao Hu

Förderung

  • NIAID NIH HHS
  • NCI NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • National Cancer Institute
  • Chung-Ho Chen Cancer Research Fund

Zitieren

APA

Kumar, N., Ma, Z., Long, F., Bonam, S. R., Lai, H. T., Wu, S. Y., Chen, H., Hazell, N. C., Bei, J., Liu, X., Chen, Y., Wei, Z., Chiang, C. M., Zhou, J., & Hu, H. (2026). Mechanistic insights and in vivo HIV suppression by the BRD4-targeting small molecule ZL0580. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1013449

Vancouver

Kumar N, Ma Z, Long F, Bonam SR, Lai HT, Wu SY, et al. Mechanistic insights and in vivo HIV suppression by the BRD4-targeting small molecule ZL0580. PLOS Pathogens. 2026. doi:10.1371/journal.ppat.1013449

BibTeX
@article{Kumar2026,
  author = {Kumar, Naveen and Ma, Zonghui and Long, Fuquan and Bonam, Srinivasa Reddy and Lai, Hsien-Tsung and Wu, Shwu-Yuan and Chen, Haiying and Hazell, Nicholas C and Bei, Jiani and Liu, Xuefeng and Chen, Yeqing and Wei, Zhi and Chiang, Cheng-Ming and Zhou, Jia and Hu, Haitao},
  title = {Mechanistic insights and in vivo HIV suppression by the BRD4-targeting small molecule ZL0580},
  journal = {PLOS Pathogens},
  year = {2026},
  doi = {10.1371/journal.ppat.1013449}
}
Kostenlos starten →